nach oben

International Journal of Clinical Oncology

05.06.2019 | Invited Review Article

Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era

verfasst von: Minoru Suzuki

Erschienen in: International Journal of Clinical Oncology

Einloggen, um Zugang zu erhalten

Abstract

Boron neutron capture therapy (BNCT) has a unique property of tumor-cell-selective heavy-particle irradiation. BNCT can form large dose gradients between cancer cells and normal cells, even if the two types of cells are mingled at the tumor margin. This property makes it possible for BNCT to be used for pre-irradiated locally recurrent tumors. Shallow-seated, locally recurrent lesions have been treated with BNCT because of the poor penetration of neutrons in the human body. BNCT has been used in clinical studies for recurrent malignant gliomas and head and neck cancers using neutron beams derived from research reactors, although further investigation is warranted because of the small number of patients. In the latter part of this review, the development of accelerator-based neutron sources is described. BNCT for common cancers will become available at medical institutes that are equipped with an accelerator-based BNCT system. Multiple metastatic lung tumors have been investigated as one of the new treatment candidates because BNCT can deliver curative doses of radiation to the tumors while sparing normal lung tissue. Further basic and clinical studies are needed to move toward an era of accelerator-based BNCT when more patients suffering from refractory cancers will be treated.

Locher GL (1936) Biological effects and therapeutic possibilities of neutron. Am J Roentgenol Radium Ther 36:1–13

Coderre JA, Morris GM (1999) The radiation biology of boron neutron capture therapy. Radiat Res 151:1–18PubMed

Soloway AH, Hatanaka H, Davis MA (1967) Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compound. J Neurosurg 9:200–209

Hatanaka HA (1975) Revised boron-neutron capture therapy for malignant brain tumors. J. Neurol 209:81–94PubMed

Mishima Y, Honda C, Ichikawa M et al (1989) Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10b-compound. Lancet 334:388–389

Wongthai P, Hagiwara K, Miyoshi Y et al (2015) Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci 106:279–286PubMedPubMedCentral

Morris GM, Coderre JA, Hopewell JW et al (1994) Response of the central nervous system to boron neutron capture therapy: evaluation using rat spinaro cord. Radiother Oncol 32:249–255PubMed

Hatanaka H, Nakagawa Y (1994) Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28:1061–1066PubMed

Diaz AZ (2003) Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 62:101–109PubMed

10.

Busse PM, Harling OK, Palmer MR et al (2003) A clinical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 62:111–121PubMed

11.

Vos MJ, Turowski B, Zanella FE et al (2005) Radiologic findings in patients with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int J Radiat Oncol Biol Phys 61:392–399PubMed

12.

Kankaanranta L, Seppälä T, Koivunor H et al (2011) L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a phase I study. Int J Radiat Oncol Biol Phys 80:369–376PubMed

13.

Herriksson R, Capala J, Michanek A et al (2008) Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of bornophenylalanine (BPA). Radiother Oncol 88:183–191

14.

Pelettier L, H-Stenstam B, Rezaei A et al (2008) An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand 117:191–197

15.

Yamamoto T, Matsumura A, Nakai K et al (2004) Current clinical results of the Tsukuba BNCT trial. Appl Radiat Isot 61:1089–1093PubMed

16.

Yamamoto T, Nakai K, Kageji T et al (2009) Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 91:80–84PubMed

17.

Kageji T, Nagahiro S, Matsuzaki K et al (2006) Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome. Int J Radiat Oncol Biol Phys 65:1446–1455PubMed

18.

Kageji T, Mizobuchi Y, Nagahiro S et al (2011) Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot 69:1823–1825PubMed

19.

Kageji T, Mizobuchi Y, Nagahiro S et al (2011) Long-survivors of glioblastoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot 69:1800–1802PubMed

20.

Miyatake S, Kawabata S, Kuroiwa T et al (2005) Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 103:1000–1009PubMed

21.

Kawabata S, Miyatake S, Kuroiwa T et al (2009) Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res (Tokyo) 50:51–60

22.

Miyatake S, Kawabata S, Yokoyama K et al (2009) Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 91:199–206PubMed

23.

Kawabata S, Miyatake S, Hiramatsu R et al (2011) Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multifomre-study design and current status report. Appl Radiat Isot 69:1796–1799PubMed

24.

Yamamoto T, Nakai K, Nariai T et al (2011) The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation. Appl Radiat Isot 69:1817–1818PubMed

25.

Nakai K, Yamamoto T, Aiyama H et al (2011) Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: a recursive partitioning analysis of BNCT patients. Appl Radiat Isot 69:1790–1792PubMed

26.

Shiba H, Takeuchi K, Hiramatsu R et al (2018) Boron neutron capture therapy combined with early successive bevacizumab treatment for recurrent malignant gliomas—a pilot study. Neurol Med Chir (Tokyo) 58:487–494

27.

Miyatake SI, Kawabata S, Hiramatsu R et al (2018) Boron neutron capture therapy of malignant gliomas. Prog Neural Surg 32:48–56

28.

Kondo N, Barth RF, Miyatake SI et al (2017) Cerebrospinal fluid dissemination of high-grade glioma following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R^132H mutation-negative glioblastoma. J Neurooncol 133:107–118PubMedPubMedCentral

29.

Kato I, Ono K, Sakurai Y et al (2004) Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61:1069–1073PubMed

30.

Ariyoshi Y, Miyatake S, Kimura Y et al (2007) Boron neutron capture therapy using epithemal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep 18:861–866PubMed

31.

Kimura Y, Ariyoshi Y, Miyatake S et al (2009) Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: a case report. Appl Radiat Isot 67:S47–S49PubMed

32.

Suzuki M, Sakurai Y, Nagata K et al (2006) Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 66:1523–1527PubMed

33.

Fuwa N, Suzuki M, Sakurai Y et al (2008) Treatment results of boron neutron capture therapy using intra-arterial administration of boron compounds for recurrent head and neck cancer. Br J Radiol 81:749–752PubMed

34.

Kankaanranta L, Saarilahti K, Mäkitie A et al (2011) Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiother Oncol 99:98–99PubMed

35.

Wang LW, Wang SI, Chu PY et al (2011) BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor. Appl Radiat Isot 69:1803–1806PubMed

36.

Kankaanranta L, Seppälä T, Koivunoro H et al (2012) Boron neutron capture therapy in the treatment of locally recurred head and neck cancer: final analysis of a phase I/II traial. Int J Radiat Oncol Biol Phys 82:e67–75PubMed

37.

Suzuki M, Kato I, Aihara T et al (2014) Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res 55:146–153PubMed

38.

Aihara T, Morita N, Kamitani N et al (2014) BNCT for advanced or recurrent head and neck cancer. Appl Radiat Isot 88:12–15PubMed

39.

Aihara T, Hiratsuka J, Ishikawa H et al (2015) Fatal carotid blowout syndrome after BNCT for head and neck cancers. Appl Radiat Isot 88:202–206

40.

Wang LW, Chen YW, Ho CY et al (2014) Fractionated BNCT for locally recurrent head and neck cancer: experience from a phase I/II clinical trial at Tsing Hua open-pool reactor. Appl Radiat Isot 88:64–68

41.

Wang LW, Liu YH, Chou FI et al (2018) Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua open pool reactor. Cancer Commun (Lond) 38:37. https://doi.org/10.1186/s40880-018-0295-y CrossRef

42.

Barth RF, Vicente MG, Harling OK et al (2012) Current status of boron neutron capture therapy of high-grade gliomas and recurrent head and neck cancer. Radiat Oncol 7:146. https://doi.org/10.1186/1748-717X-7-146 CrossRefPubMedPubMedCentral

43.

Tanaka H, Sakurai Y, Suzuki M et al (2009) Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy. Nucl Instrum Methods Phys Res B 267:1970–1977

44.

Tanaka H, Sakurai Y, Suzuki M et al (2009) Improvement of dose distribution in phantom by using epithermal neutron source based on the Be(p, n) reaction using a 30 MeV proton cyclotron accelerator. Appl Radiat Isot 67:S258–261PubMed

45.

Tanaka H, Sakurai Y, Suzuki M et al (2011) Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Appl Radiat Isot 69:1642–1645PubMed

46.

Falías RO, Bortolussi S, Menéndez PR et al (2014) Exploring boron neutron capture therapy for non-small cell lung cancer. Phys Med 30:888–897

47.

Farías RO, Garabalino MA, Ferraris S et al (2015) Toward a clinical application of ex situ boron neutron capture therapy for lung tumors at the RA-3 reactor in Argentina. Med Phys 42:4161–4173PubMed

48.

Suzuki M, Endo K, Satoh H et al (2008) A novel concept of treatment of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother Oncol 88:192–195PubMed

Titel: Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era
verfasst von: Minoru Suzuki
Publikationsdatum: 05.06.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01480-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie